Theravance Biopharma Inc (TBPH) Stock Analysis

What Theravance Biopharma Inc does

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Key metrics

ETFs linked to TBPH

Broad-market and Healthcare sector ETFs an investor holding Theravance Biopharma Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TBPH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Theravance Biopharma Inc?

Theravance Biopharma Inc trades under the ticker TBPH on NASDAQ.

Which exchange is TBPH listed on?

TBPH is listed on NASDAQ.

What sector does Theravance Biopharma Inc operate in?

Theravance Biopharma Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TBPH in a portfolio?

PortView shows TBPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.